Matinas Biopharma Holdings, Inc. annual report, FY2014

Matinas BioPharma Holdings, Inc. — FY2014 Form 10-K

Reporting period: Fiscal year ended December 31, 2014; compared with FY2013. The filing is an annual report, not a standalone fourth-quarter report, and does not provide separate Q4 financial results. The January 29, 2015 Aquarius acquisition occurred after year-end and is not included in FY2014 results.

Business context

Matinas was a development-stage biopharmaceutical company with no product revenue. Its pre-acquisition focus was MAT9001, an omega-3 prescription candidate for severe hypertriglyceridemia. The Aquarius acquisition expanded the pipeline to include cochleate-delivery candidates MAT2203, an oral amphotericin B formulation, and MAT2501, an oral amikacin formulation, alongside the early-stage MAT8800 discovery program. The cochleate platform is exclusively licensed worldwide from Rutgers University.

Financial performance and liquidity

Metric	FY2014	FY2013
Revenue	$0	$0
Research and development expense	$5.18 million	$1.76 million
General and administrative expense	$5.29 million	$1.95 million
Total operating expenses	$10.46 million	$3.71 million
Net loss	$10.22 million	$3.71 million
Basic and diluted loss per share	$0.32	$0.20
Net cash used in operating activities	$7.96 million	$2.99 million
Net cash used in investing activities	$0.29 million	$0.09 million
Net cash from financing activities	$0	$13.50 million

• Operating expenses rose $6.75 million year over year, reflecting expanded MAT9001 manufacturing-process development, clinical and preclinical work, staffing, stock compensation, and public-company costs. R&D spending was approximately $5.2 million, primarily supporting MAT9001.
• Cash and cash equivalents were $2.59 million at December 31, 2014, down from $10.84 million a year earlier. The balance sheet also reported $100,000 of current restricted cash.
• Current assets were $2.81 million and current liabilities $1.12 million. Total liabilities were $1.13 million, including lease liabilities; the filing reports no material borrowing or conventional debt balance.
• Accumulated deficit was $14.05 million. No revenue-based margins are meaningful because the company had no revenue.
• Management said year-end cash was expected to fund operating expenses and capital expenditures only through April 2015. The auditor’s report includes a going-concern emphasis, citing recurring losses, negative operating cash flows, and limited liquidity. The financial statements were not adjusted for the outcome of this uncertainty.

Material changes and subsequent events

• On January 29, 2015, Matinas acquired Aquarius. It issued 4,608,020 shares at closing, subject to adjustment up to 5 million, and may issue up to 3 million additional shares upon specified clinical and regulatory milestones. The filing says former Aquarius holders owned approximately 8% of the company on a fully diluted basis after closing, before potential milestone shares.
• The acquisition added the cochleate platform and anti-infective pipeline. The filing estimates approximately $400,000 of one-time transaction liabilities and expected minimal liquidity impact for the remainder of 2015; acquisition accounting and Aquarius results were to be reflected after closing.
• Cash used in operations increased substantially as development activity and overhead grew; no financing cash was raised in 2014, following the $13.5 million net financing inflow in 2013.

Outlook, risks, and unusual items

• MAT2203: Management expected to start and complete an NIH/NIAID-collaborative, NIH-funded Phase 2a study in 2015, with results expected in Q4 2015. Its completed single-dose Phase 1a study in 48 healthy volunteers was described as showing a positive safety and tolerability profile. Human efficacy and the proposed safety advantages remain unproven.
• MAT2501: Preclinical toxicology work was underway, with an IND filing targeted for later in 2015. Animal proof-of-principle findings do not establish human safety or efficacy.
• MAT9001: The FDA accepted its IND in December 2014 without a clinical hold, but recommended revisions to planned comparative toxicity and pharmacokinetic studies. The company submitted modified protocols in Q1 2015 and planned to assess the program after completing the studies and further FDA dialogue. A separate PK/PD study enrolled 42 subjects; after an interim review, the steering committee recommended no further enrollment, and topline results were expected in Q2 2015. Management said FDA approval was not expected before 2017 at the earliest.
• MAT8800: Preclinical animal studies of candidate omega-3 compositions were underway; management expected completion in Q2 or Q3 2015.
• The company expected increasing losses and cash needs and had no committed external funding source beyond limited NIH grant support. It warned that additional capital might not be available on acceptable terms or at all, potentially forcing delays, reductions, or termination of programs. Equity financing could dilute shareholders; partnerships could require surrendering rights.
• Other key risks include clinical and regulatory failure or delay, reliance on Rutgers and third-party manufacturers and CROs, lack of commercial infrastructure, competition, reimbursement and pricing uncertainty, and difficulty integrating Aquarius. If specified milestones do not occur and cochleate development is discontinued under the merger agreement, the technology may have to be transferred back to former Aquarius shareholders.
• Unusual noncash costs included approximately $1.97 million of stock-based compensation in FY2014. The company also recognized a $269,127 benefit from selling New Jersey net operating losses. Federal and state deferred tax assets were fully offset by a valuation allowance.

Investor verification points

• Confirm subsequent financing, cash runway, and actual liquidity after the April 2015 runway estimate.
• Review MAT2203 Phase 2a initiation, completion, results, and any later safety or efficacy findings.
• Check MAT9001 study results, FDA feedback, and the company’s decision on whether to continue development.
• Verify MAT2501 IND and clinical progress, and MAT8800 preclinical outcomes.
• Assess Aquarius acquisition accounting, final share adjustments, milestone-share dilution, and any potential technology reversion provisions.
• Review the going-concern disclosure and internal-control history; the filing states disclosure controls were effective at a reasonable-assurance level, while prior material weaknesses had been identified and management said remediation steps were underway.